(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Minerva Neurosciences's earnings in 2026 is -$293,423,177.On average, 4 Wall Street analysts forecast NERV's earnings for 2026 to be -$35,091,209, with the lowest NERV earnings forecast at -$44,529,356, and the highest NERV earnings forecast at -$24,536,584. On average, 4 Wall Street analysts forecast NERV's earnings for 2027 to be -$26,704,631, with the lowest NERV earnings forecast at -$27,989,881, and the highest NERV earnings forecast at -$24,990,965.
In 2028, NERV is forecast to generate -$11,034,971 in earnings, with the lowest earnings forecast at -$10,602,228 and the highest earnings forecast at -$11,359,529.